Citigroup Issues Pessimistic Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price

Hims & Hers Health (NYSE:HIMS - Get Free Report) had its price objective reduced by Citigroup from $27.00 to $25.00 in a research note issued on Friday,Benzinga reports. The firm presently has a "sell" rating on the stock. Citigroup's target price would indicate a potential downside of 11.03% from the company's previous close.

HIMS has been the subject of a number of other reports. Needham & Company LLC increased their target price on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a "buy" rating in a report on Tuesday, February 25th. Truist Financial decreased their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research note on Thursday, April 10th. Leerink Partners boosted their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a report on Tuesday, February 25th. Piper Sandler boosted their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a research note on Tuesday, February 25th. Finally, Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research report on Wednesday, February 19th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $38.08.

Hims & Hers Health Stock Performance

HIMS traded down $0.04 during mid-day trading on Friday, reaching $28.10. 13,717,774 shares of the stock were exchanged, compared to its average volume of 15,649,401. The company has a 50 day moving average price of $34.24 and a two-hundred day moving average price of $31.08. The stock has a market capitalization of $6.24 billion, a PE ratio of 63.87 and a beta of 1.65. Hims & Hers Health has a 1 year low of $11.20 and a 1 year high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Sell-side analysts expect that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Insider Activity

In related news, CEO Andrew Dudum sold 100,000 shares of the business's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $35.22, for a total value of $3,522,000.00. Following the completion of the sale, the chief executive officer now directly owns 27,918 shares of the company's stock, valued at $983,271.96. The trade was a 78.18 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Irene Becklund sold 2,203 shares of the business's stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $28.78, for a total transaction of $63,402.34. Following the completion of the sale, the insider now directly owns 8,007 shares of the company's stock, valued at approximately $230,441.46. This trade represents a 21.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 712,998 shares of company stock valued at $27,992,450. 17.71% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently bought and sold shares of the company. MML Investors Services LLC acquired a new position in shares of Hims & Hers Health in the third quarter worth $197,000. Barclays PLC boosted its position in shares of Hims & Hers Health by 9.7% in the third quarter. Barclays PLC now owns 308,363 shares of the company's stock worth $5,680,000 after buying an additional 27,231 shares during the period. Principal Financial Group Inc. boosted its position in shares of Hims & Hers Health by 102.0% in the third quarter. Principal Financial Group Inc. now owns 290,414 shares of the company's stock worth $5,349,000 after buying an additional 146,621 shares during the period. GAMMA Investing LLC lifted its stake in shares of Hims & Hers Health by 2,173.7% in the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company's stock worth $54,000 after acquiring an additional 2,152 shares in the last quarter. Finally, Cadent Capital Advisors LLC lifted its stake in shares of Hims & Hers Health by 1.5% in the fourth quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company's stock worth $1,745,000 after acquiring an additional 1,060 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.